Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy

Amgen's $13.4 billion cash offer has won the bidding war for Celgene and Bristol-Myers Squibb's psoriasis drug, Otezla. Here's why the Goliath biopharma is betting so big on its success. Also, new data from The Medicines Company suggests a new cholesterol-busting drug is on it's way to approval. Stocks: CELG, BMY, AMGN, MDCO Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter